BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.
| Product | Description | |
|---|---|---|
| EIDD-1931 | EIDD-1931 is a ribonucleoside analog that exhibits potential antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-1931 induces mutations in RNA virions, inhibiting SARS-CoV-2 and other coronavirus in mice and human airway epithelial cells. Synonyms: N4-Hydroxycytidine; N(4)-Hydroxycytidine; Uridine, 4-oxime; Beta-D-N4-hydroxycytidine. Grade: 99.73%. CAS No. 3258-2-4. Molecular formula: C9H13N3O6. Mole weight: 259.22. |  |
| EIDD-2749 | 4'-Fluorouridine is an orally active RdRp inhibitor. It effectively blocks the replication of RSV and SARS-CoV-2. Synonyms: 4'-fluorouridine; 1613589-24-4; 4'-C-Fluoro-uridine; 1-[(2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione; 1613591-91-5; SCHEMBL6839661; RDCYLPRXPILMRP-JVZYCSMKSA-N; AMY30709; EX-A6732; DA-70078; MS-23688; 4'-fluorouridine (4'-FlU, EIDD-2749)?; 1-((2R,3R,4S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione. Grade: 98%. CAS No. 1613589-24-4. Molecular formula: C9H11FN2O6. Mole weight: 262.19. | |
| EIDD-2801 | EIDD-2801, derived from N4-hydroxycytidine, is an oral bioavailable broad-spectrum antiviral compound that is effective against SARS-CoV2 infection. Uses: Antiviral agents. Synonyms: Molnupiravir; EIDD 2801; EIDD2801; MK-4482; WHO 11853; N4-Hydroxycytidine, 5'-isopropyl ester; beta-D-N4 Hydroxycytidine-5'-isopropyl ester; Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)-; EIDD 1931-isopropyl ester; Lagevrio; MK-4482; β-D-N4 hydroxycytidine-5'-isopropyl ester. Grade: 95%. CAS No. 2492423-29-5. Molecular formula: C13H19N3O7. Mole weight: 329.31. | |
| eIF4A3-IN-1 | eIF4A3-IN-1 is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor. It binds to a non-ATP binding site of eIF4A3 and shows significant cellular nonsense-mediated RNA decay (NMD) inhibition at 10 and 3 μM and can be as a probe for further study of eIF4A3, the exon junction complex (EJC), and NMD. Synonyms: eIF4A3-IN-1; 2095486-67-0; CHEMBL4073833; BDBM50265561; AKOS040733081; MS-30511; HY-101513; CS-0021616; 3-[4-[(3S)-4-(4-bromobenzoyl)-3-(4-chlorophenyl)piperazine-1-carbonyl]-5-methylpyrazol-1-yl]benzonitrile. Grade: 99%. CAS No. 2095486-67-0. Molecular formula: C29H23BrClN5O2. Mole weight: 588.88. | |
| eIF4A3-IN-2 | eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 inhibitor with an IC50 of 110 nM. Synonyms: eIF4A3 inhibitor, 2. Grade: 99%. CAS No. 2095677-20-4. Molecular formula: C25H19Br2ClN4O2. Mole weight: 602.71. | |
| eIF4A3-IN-4 | eIF4A3-IN-4 is an inhibitor of eukaryotic initiation factor 4A (eIF4A) with an IC50 of 8.6 μM. Synonyms: eIF4A3-IN-4; CS-0256185. Molecular formula: C24H20N2O5. Mole weight: 416.43. | |
| eIF4A3-IN-5 | eIF4A3-IN-5, a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII, has the potential to study eIF4A dependent diseases, including cancer. (Extracted from patent US20170145026A1). Synonyms: 6H-Cyclopenta[4,5]furo[3,2-c]pyridine-7-carboxylic acid, 5a-(4-cyanophenyl)-5a,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-, (5aR,6S,7R,8R,8aS)-. CAS No. 2100145-31-9. Molecular formula: C26H22N2O7. Mole weight: 474.46. | |
| eIF4A3-IN-6 | eIF4A3-IN-6, a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII, has the potential to study eIF4A dependent diseases, including cancer. (Extracted from patent US20170145026A1). Synonyms: Benzonitrile, 4-[(5aR,6S,7S,8R,8aS)-7-(aminomethyl)-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl]-. CAS No. 2100133-77-3. Molecular formula: C26H25N3O5. Mole weight: 459.49. | |
| eIF4A3-IN-7 | eIF4A3-IN-7 is an effective inhibitor of eIF4A3, which has the potential to study cancer and other dysproliferative diseases. (extracted from patent WO2019161345A1, Compound 8). Synonyms: 1H-Cyclopenta[b]benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-3a-(4-hydroxyphenyl)-6,8-dimethoxy-3-phenyl-, (1R,2R,3S,3aR,8bS)-. CAS No. 2374759-82-5. Molecular formula: C26H25NO7. Mole weight: 463.48. | |
| eIF4E-IN-1 | eIF4E-IN-1, a potent eIF4E inhibitor, inhibits immunosuppression components such as the immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immunosuppression in certain diseases, such as cancer and infectious diseases. (Extracted from patent WO2021003194A1, compound Y). Synonyms: Thieno[3,2-b]pyridine-3-carboxylic acid, 7-[5-chloro-2-[2-[5-cyano-2-methyl-6-(4-methyl-1-piperazinyl)-4-oxo-7-(trifluoromethyl)-3(4H)-quinazolinyl]ethoxy]phenyl]-5-methyl-. CAS No. 2573979-31-2. Molecular formula: C33H28ClF3N6O4S. Mole weight: 697.13. | |
| eIF4E-IN-2 | eIF4E-IN-2, a potent inhibitor of eukaryotic initiation factor 4e (eIF4e), has the potential to study eIF4e-dependent diseases, including cancer. (Extracted from patent WO2021003157A1, compound 1188). Synonyms: 7-(5-chloro-2-(3-(5-cyano-6-((1-(3,3-difluorocyclobutyl)piperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)-N-(methylsulfonyl)thieno[3,2-b]pyridine-3-carboxamide. CAS No. 2575840-38-7. Molecular formula: C37H33ClF2N8O4S2. Mole weight: 791.29. | |
| eIF4E-IN-3 | eIF4E-IN-3, a potent inhibitor of eukaryotic initiation factor 4e (eIF4e), has the potential to study eIF4e-dependent diseases, including cancer. (Extracted from patent WO2021003157A1, compound 485). Synonyms: Thieno[3,2-b]pyridine-3-carboxylic acid, 7-[5-chloro-2-[2-[5-cyano-2-methyl-6-[(4-methyl-1-piperazinyl)methyl]-4-oxo-7-(trifluoromethyl)-3(4H)-quinazolinyl]ethoxy]phenyl]-5-methyl-. CAS No. 2573979-29-8. Molecular formula: C34H30ClF3N6O4S. Mole weight: 711.15. | |
| EIPA | EIPA is a TRPP3 channel inhibitor (IC50 = 10.5 μM). EIPA also acts as an Na+/H+ exchange inhibitor that suppresses the Na+/H+ exchanger (NHE). Uses: Epithelial sodium channel blockers. Synonyms: Ethylisopropylamiloride; L 593754; MH 12-43; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]-2-pyrazinecarboxamide. Grade: ≥98% by HPLC. CAS No. 1154-25-2. Molecular formula: C11H18ClN7O. Mole weight: 299.76. | |
| EIPA hydrochloride | EIPA is a TRPP3 channel inhibitor (IC50 = 10.5 μM). EIPA also acts as an Na+/H+ exchange inhibitor that suppresses the Na+/H+ exchanger (NHE). Synonyms: L593754 hydrochloride; L 593754 hydrochloride; L-593754 hydrochloride; Ethylisopropylamiloride hydrochloride; MH 12-43 hydrochloride; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]-2-pyrazinecarboxamide hydrochloride. CAS No. 1345839-28-2. Molecular formula: C11H19Cl2N7O. Mole weight: 336.22. | |
| EIT hydrobromide | EIT hydrobromide is a potent and reversible inhibitor of isoform II NO synthase (IC50 = 13 nM; approximately 20- and 30-fold selective over isoforms I and III respectively). Uses: Enzyme inhibitors. Synonyms: (S)-Ethylisothiourea hydrobromide; 2-Ethyl-2-thiopseudourea hydrobromide; Ethiron bromide. CAS No. 1071-37-0. Molecular formula: C3H8N2S.HBr. Mole weight: 185.08. | |
| EL-102 | EL102, a HIF1α inhibitor, has been found to have potential effect in restraining polymerisation of tubulin and influencing the stability of microtubule. IC50: 20-40 nM. Uses: El102 is a hif1α inhibitor that has been found to have potential effect in restraining polymerisation of tubulin and influencing the stability of microtubule. Synonyms: EL 102; EL102. Grade: 95%. CAS No. 1233948-61-2. Molecular formula: C19H16N2O3S2. Mole weight: 384.47. | |
| ELA-11 (human) | ELA-11 (human) is a high affinity apelin receptor agonist (Ki = 14 nM). It is a bioactive fragment of ELA-32. ELA-11 (human) inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro. Synonyms: Elabela/Toddler-11; 1784687-32-6; ELA-11; GTPL8526; CHEMBL3809035; BDBM50172365. Grade: ≥95%. CAS No. 1784687-32-6. Molecular formula: C58H90N16O13S2. Mole weight: 1283.57. | |
| ELA-11 (human) acetate | ELA-11 (human) is a high affinity apelin receptor agonist (Ki = 14 nM). It is a bioactive fragment of ELA-32. ELA-11 (human) acetate inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro. Molecular formula: C60H94N16O15S2. Mole weight: 1343.61. | |
| ELA-14 negative control | Negative control for ELA-14. Synonyms: H-Pyr-Arg-Arg-Cys-Met-Pro-Leu-His-Ser-Ala-Val-Pro-Phe-Pro-OH. CAS No. 1885873-44-8. Molecular formula: C72H112N22O17S2. Mole weight: 1621.93. | |
| ELA-21 (human) | ELA-21 (human) is a high affinity apelin receptor agonist that binds apelin receptors in left ventricle from normal and pulmonary arterial hypertensive (PAH) hearts (pKi values are 9.31 and 9.46, respectively). It is a bioactive fragment of ELA-32. Grade: ≥98%. Molecular formula: C112H184N40O25S3. Mole weight: 2587.12. | |
| ELA-32 (human) | ELA-32 (human) is a potent apelin receptor agonist (IC50 = 0.27 nM; Kd=0.51 nM) stimulating the PI3K/AKT pathway and promoting self-renewal of hESCs via cell-cycle progression and protein translation. It also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. Synonyms: ELA-32 (human); ELA 32 (human); ELA32 (human). Grade: >98%. CAS No. 1680205-79-1. Molecular formula: C170H289N63O39S4. Mole weight: 3967.8. | |
| Elacestrant | Elacestrant, also referred to RAD1901, is a selective and orally available estrogen receptor (ERR) degrader (IC50= 48 and 870 nM for ERα and ERβ, respectively) and selective estrogen receptor modulator (SERM). Synonyms: RAD1901; RAD-1901; RAD 1901. CAS No. 722533-56-4. Molecular formula: C30H38N2O2. Mole weight: 458.65. | |
| Elacestrant dihydrochloride | Elacestrant dihydrochloride is an orally available selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. It is also a selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Synonyms: RAD1901 dihydrochloride; (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride; 2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, (6R)-, hydrochloride (1:2). Grade: 98%. CAS No. 1349723-93-8. Molecular formula: C30H40Cl2N2O2. Mole weight: 531.56. | |
| Elacestrant S enantiomer | Elacestrant S enantiomer is a low activity enantiomer of Elacestrant, which is a selective and orally bioavailable small-molecule SERD (IC50s = 48 and 870 nM for ERα and ERβ, respectively). Synonyms: RAD1901 S enantiomer; 2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, (6S)-; (6S)-6-[2-(Ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl]-5,6,7,8-tetrahydro-2-naphthalenol. CAS No. 2309762-29-4. Molecular formula: C30H38N2O2. Mole weight: 458.63. | |
| Elacestrant S enantiomer dihydrochloride | Elacestrant S enantiomer dihydrochloride is a low activity enantiomer of Elacestrant, which is a selective and orally bioavailable small-molecule SERD (IC50s = 48 and 870 nM for ERα and ERβ, respectively). Synonyms: RAD1901 S enantiomer dihydrochloride; (6S)-6-[2-(Ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl]-5,6,7,8-tetrahydro-2-naphthalenol dihydrochloride; 2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, (6S)-, hydrochloride (1:2). Grade: ≥95%. CAS No. 2309762-30-7. Molecular formula: C30H40Cl2N2O2. Mole weight: 531.56. | |
| Elacridar | Elacridar hydrochloride (GF120918A) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects. Synonyms: GF120918; GF-120918; GF 120918; GF-120918A; GF120918A; GF 120918A; GG 918; D03968. Elacridar hydrochloride. CAS No. 143664-11-3. Molecular formula: C34H33N3O5. Mole weight: 563.654. | |
| Elacridar hydrochloride | Elacridar is an orally bioavailable inhibitor of P-glycoprotein (P-gp) and ABCG2. Synonyms: Elacridar HCl; N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide hydrochloride. CAS No. 143851-98-3. Molecular formula: C34H33N3O5.HCl. Mole weight: 600.10. | |
| Elacridar maleate | Elacridar maleate is a potent and selective inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), two key efflux transporters involved in multidrug resistance and drug disposition. Structurally, it is a third-generation multidrug resistance modulator, with the maleate salt form improving its solubility and stability. By inhibiting these transporters, elacridar enhances the bioavailability and brain penetration of various drugs that are P-gp or BCRP substrates, making it a valuable tool in pharmacokinetics and drug development studies. Elacridar maleate is widely investigated for overcoming drug resistance in cancer therapy and improving central nervous system drug delivery. Synonyms: 4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-, (2Z)-2-butenedioate (1:1); 4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-, (Z)-2-butenedioate (1:1); Elacridar (2Z)-2-butenedioate; GF 120918 maleate; GF 129018 maleate; GG 918 maleate; GW 0918 maleate. Grade: ≥95%. CAS No. 143851-84-7. Molecular formula: C34H33N3O5.C4H4O4. Mole weight: 679.72. | |
| Elacytarabine | Elacytarabine (CP-4055) is the lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As a prodrug, CP-4055 is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, CP-4055 shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine. Synonyms: CP-4055; CP 4055; CP4055; 5'-O-(Elaidoyl) 1-beta-D-arabinofuranosylcytosine; 5'-Oleoyl cytarabine; (E)-((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl octadec-9-enoate. CAS No. 188181-42-2. Molecular formula: C27H45N3O6. Mole weight: 507.67. | |
| Elafibranor | Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and total cholesterol in the liver of ApoE2-KI wild-type mice. Elafibranor is identified as a drug candidate for the treatment of cardiometabolic diseases such as diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD). Synonyms: Propanoic acid, 2-[2,6-dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-; 2-[2,6-Dimethyl-4-[(1E)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methylpropanoic acid; (E)-1-[4-(Methylthio)phenyl]-3-[3,5-dimethyl-4-[(carboxydimethylmethyl)oxy]phenyl]prop-2-en-1-one; GFT 505; GFT-505; GFT505. Grade: ≥95%. CAS No. 923978-27-2. Molecular formula: C22H24O4S. Mole weight: 384.49. | |
| Elagolix | Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels. To date, elagolix has been studied in over 20 clinical trials totaling more than 1,000 subjects. A Phase 2a trial of elagolix for the treatment of uterine fibroids is also ongoing. Endometriosis can be a debilitating disease that affects millions of women around the world and the exploration of new treatments could offer other options for women with this disease. Synonyms: Elagolix, Elagolix sodium, NBI-56418; NBI 56418; NBI56418. CAS No. 834153-87-6. Molecular formula: C32H30F5N3O5. Mole weight: 631.6. | |
| Elagolix-3-methoxy Desfluoro impurity | An impurity of Elagolix sodium, a medication indicated for the treatment of moderate to severe pain associated with endometriosis. Synonyms: (R)-4-((2-(3-(2-fluoro-6-(trifluoromethyl)benzyl)-5-(3-methoxyphenyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)amino)butanoic acid. Grade: 95%. Molecular formula: C32H31F4N3O5. Mole weight: 613.6. | |
| Elagolix (S)-enantiomer | Elagolix (S)-enantiomer is an enantiomer of Elagolix sodium, a medication indicated for the treatment of moderate to severe pain associated with endometriosis. Grade: 95%. CAS No. 2409132-65-4. Molecular formula: C32H30F5N3O5. Mole weight: 631.6. | |
| Elagolix sodium | Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma. Elagolix was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued. Uses: Endometriosis; uterine leiomyoma. Synonyms: Sodium (R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethyl)amino)butanoate; NBI56418; NBI-56418; NBI 56418. Grade: 98%. CAS No. 832720-36-2. Molecular formula: C32H29F5N3NaO5. Mole weight: 653.58. | |
| Elaidamide | Elaidamide has been found in the cerebrospinal fluid of sleep-deprived cats. Elaidamide is a fatty acid amide that inhibits rat microsomal epoxide hydrolase (mEH; Ki = 70 nM) and porcine pancreatic and human synovial phospholipase A2 (PLA2). Uses: Food additives. Synonyms: Elaidoylamide; (E)-9,10-Octadecenamide; 9E-octadecenamide. Grade: ≥95%. CAS No. 4303-70-2. Molecular formula: C18H35NO. Mole weight: 281.5. | |
| Elamipretide Acetate | Elamipretide is a small mitochondrially-targeted tetrapeptide antioxidant. Synonyms: MTP 131 acetate; MTP131 acetate; MTP-131 acetate. CAS No. 1334953-95-5. Molecular formula: C34H53N9O7. Mole weight: 699.85. | |
| Elastatinal | Elastatinal is a potent and irreversible inhibitor of pancreatic elastase. It is a much stronger inhibitor of pancreatic elastase than the leukocyte-derived enzyme. It can also inhibit elastase-like protease collagenolytic protease from C. maenas digestive glands. Synonyms: (2S)-2-[(4S)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl]-N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]glycyl-N1-[(1S)-1-methyl-2-oxyethyl]-L-glutamamide. Grade: ≥ 95 %. CAS No. 51798-45-9. Molecular formula: C21H36N8O7. Mole weight: 512.56. | |
| Elbanizine | Elbanizine is an antihistamine which is used for the treatment of allergic asthma. Synonyms: 1-(2-((2,6-dimethyl-3-nitro-4-pyridyl)amino)ethyl)-4-(diphenylmethyl)piperazine. Grade: >98.0%. CAS No. 110629-41-9. Molecular formula: C26H31N5O2. Mole weight: 445.57. | |
| Elbasvir | Elbasvir has been found to restrain viral phosphoprotein so that could be used against hepatitis C virus and is currently under Phase II trail. Uses: Elbasvir has been found to restrain viral phosphoprotein so that could be used against hepatitis c virus and is currently under phase ii trail. Synonyms: Elbasvir; MK-8742; UNII-632L571YDK; 632L571YDK; MK8742; MK 8742. Grade: 98%. CAS No. 1370468-36-2. Molecular formula: C49H55N9O7. Mole weight: 882.02. | |
| Eldacimibe | Eldacimibe is a Sterol O-acyltransferase inhibitor originated by Wyeth. No development was reported for Atherosclerosis and Hypercholesterolaemia in USA. Uses: Atherosclerosis; hypercholesterolaemia. Synonyms: ACA 147; ANA 147; WAY 125147; WAY ACA 147; 1,3-Dioxane-4,6-dione, 5-(((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)amino)(((4-(2,2-dimethylpropyl)phenyl)-methyl)hexylamino)methylene-2,2-dimethyl. Grade: 98%. CAS No. 141993-70-6. Molecular formula: C39H58N2O5. Mole weight: 634.89. | |
| Eldecalcitol | Eldecalcitol, a vitamin D analog, has strong effects to reduce calcium reabsorption into the body from bones, therefore increasing bone mineral density, and to increase calcium absorption in intestines. Synonyms: Edirol; ED-71; 2-(3-Hydroxypropoxy)-1,25-dihydroxyvitamin D3; 2-(3-Hydroxypropoxy)calcitriol; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3. Grade: >98%. CAS No. 104121-92-8. Molecular formula: C30H50O5. Mole weight: 490.72. | |
| Eldecalcitol Intermediate A | Eldecalcitol Intermediate A is an intermediate of eldecalcitol, a vitamin D3 analogue for the treatment of osteoporosis. Eldecalcitol is more active in bone resorption inhibition in comparison with alfacalcidol. Synonyms: 3-[(1R,2R,4Z,6R)-2,6-bis[[tert-butyl(dimethyl)silyl]oxy]-4-(2-diphenylphosphorylethylidene)-3-methylidenecyclohexyl]oxypropoxy-tert-butyl-dimethylsilane. CAS No. 200636-54-0. Molecular formula: C42H71O5PSi3. Mole weight: 771.25. | |
| Eldecalcitol Intermediate CD | Eldecalcitol Intermediate CD is a vital component used in the compound industry. Specifically designed for pharmaceutical applications, this intermediate plays a crucial role in the synthesis of Eldecalcitol, a drug used for the research of osteoporosand other bone-related disorders. Synonyms: ED71-CD ring; 25-[(triethylsilyl)oxy]de-A,B-cholestan-8-one; (1R,3aR,7aR)-7a-Methyl-1-((R)-6-methyl-6-((triethylsilyl)oxy)heptan-2-yl)hexahydro-1H-inden-4(2H)-one. CAS No. 144848-24-8. Molecular formula: C24H46O2Si. Mole weight: 394.71. | |
| Eldelumab | Eldelumab is a humanized anti-CXCL10 (IP-10) monoclonal antibody that binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab has been use for the treatment of ulcerative colitis. Synonyms: BMS-936557; MDX-1100. CAS No. 946414-98-8. | |
| Eleclazine | Eleclazine is a selective Sodium channel antagonist. Eleclazin showed a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart's electrical cycle) in patients with long QT-3 (LQT3) syndrome. Phase III clinical trilas for the treatment of Long QT syndrome, Phase II/III clinical trilas for the treatment of Hypertrophic cardiomyopathy and Phase II clinical trilas for the treatment of Ventricular arrhythmias are on-going. Uses: Long qt syndrome;hypertrophic cardiomyopathy;ventricular arrhythmias. Synonyms: GS-6615; GS 6615; GS6615; Eleclazine. 4-[(pyrimidin-2-yl)methyl]-7-[4-(trifluoromethoxy)phenyl]- 3,4-dihydro-1,4-benzoxazepin-5(2H)-one. Grade: 95%. CAS No. 1443211-72-0. Molecular formula: C21H16F3N3O3. Mole weight: 415.37. | |
| Elenbecestat | Elenbecestat is a novel, potent and orally bioavailable BACE1 inhibitor for the treatment of Alzheimer's disease (AD), which demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing. Synonyms: E2609; N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide. Grade: ≥98%. CAS No. 1388651-30-6. Molecular formula: C19H18F3N5O2S. Mole weight: 437.44. | |
| Elenestinib | Elenestinib is a next-generation KIT D816V inhibitor. Elenestinib exhibits potent inhibition of KIT D816V and an evolved pre-clinical profile with limited central nervous system penetration. Synonyms: BLU-263. CAS No. 2505078-08-8. Molecular formula: C27H29FN10O. Mole weight: 528.6. | |
| Elesclomol | Elesclomol is a HSP-90 Inhibitor, and is a small-molecule bis(thio-hydrazide amide) with oxidative stress induction, pro-apoptotic, and potential antineoplastic activities. Elesclomol induces oxidative stress, creating high levels of reactive oxygen species (ROS), such as hydrogen peroxide, in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared to normal cells, the increase in oxidative stress beyond baseline levels elevates ROS beyond sustainable levels, exhausting tumor cell antioxidant capacity, which may result in the induction of the mitochondrial apoptosis pathway. Normal cells are spared because the increase in the level of oxidative stress induced by this agent is below the threshold at which apoptosis is induced. Elesclomol is currently developed by Synta Pharmaceuticals Corp. Synonyms: STA4783; STA-4783; STA 4783, Elesclomol. CAS No. 488832-69-5. Molecular formula: C19H20N4O2S2. Mole weight: 400.52. | |
| Eletriptan | Eletriptan is Serotonin 1D receptor agonist originated by Pfizer. It is a second generation triptan drug. It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan was approved by the FDA for the acute treatment of migraine with or without aura in adults in 2002. Uses: Menstrual migraine; migraine. Synonyms: 3-[[(2R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; Eletriptan; UK 116044; UK-116,044; UK-116,044-04 [as hydrobromide]; UNII-22QOO9B8KI; Relpax free amine. Grade: 98%. CAS No. 143322-58-1. Molecular formula: C22H26N2O2S. Mole weight: 382.52. | |
| Eletriptan-d3 hydrobromide | Eletriptan-d3 is used as an internal standard for the quantification of eletriptan by GC- or LC-MS. Eletriptan is an agonist of the serotonin (5-HT) receptor types 5-HT1B and 5-HT1D. Synonyms: UK 116044-d3; 3-[[(2R)-1-methyl-d3-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole, monohydrobromide. Grade: ≥99% atom D. Molecular formula: C22H23D3N2O2S·HBr. Mole weight: 466.45. | |
| Eletriptan HBr | Eletriptan induces concentration-dependent contractions of meningeal artery, coronary artery, and saphenous vein. The potency of Eletriptan is higher in meningeal artery than in coronary artery (86-fold) or saphenous vein (66-fold). Synonyms: Eletriptan Hydrobromide; CHEBI:61176; M41W832TA3; UNII-M41W832TA3; eletriptan hydrobromide; Relpax; UK 166,044; UK 166044; UK-166,044; UK-166044. Grade: >98%. CAS No. 177834-92-3. Molecular formula: C22H26N2O2S.HBr. Mole weight: 463.43. | |
| Eletriptan N-oxide | An impurity of Eletriptan. Synonyms: 3-[[(2R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole N Oxide. Grade: > 95%. CAS No. 1217641-89-8. Molecular formula: C22H26N2O3S. Mole weight: 398.53. | |
| Elexacaftor | Elexacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector used as a medication for cystic fibrosis treatment in combination with ivacaftor and tezacaftor. Synonyms: VX-445; VX445; (S)-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-(2,2,4-trimethylpyrrolidin-1-yl)nicotinamide. Grade: 98%. CAS No. 2216712-66-0. Molecular formula: C26H34F3N7O4S. Mole weight: 597.65. | |
| Eliapixant | Eliapixant is a P2X3 receptor antagonist, which is under a clinical trial for refractory chronic cough (RCC) treatment. Synonyms: BAY 1817080. CAS No. 1948229-21-7. Molecular formula: C22H21F3N4O3S. Mole weight: 478.49. | |
| Eliglustat | Eliglustat is a glucosylceramide synthase inhibitor indicated for the long-term treatment of type 1 Gaucher disease in patients who are CYP2D6 extensive metabolizers, intermediate metabolizers , or poor metabolizers in treatment-naive and treatment-experi. Uses: Inhibits glucosylceramide synthase(gcs). Synonyms: Genz-99067; Genz 99067; Genz99067; N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide. Grade: ≥98%. CAS No. 491833-29-5. Molecular formula: C23H36N2O4. Mole weight: 404.55. | |
| Eliglustat hemitartrate | Eliglustat hemitartrate is a specific inhibitor of glucosylceramide synthase. It is under development as an oral substrate reduction therapy for Gaucher disease type 1 (GD1). It was developed by Genzyme Corp and has been listed by the FDA August 2014. Synonyms: Genz-112638; Genz 112638; Genz112638; Eliglustat tartrate; Bis(N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(pyrrolidin-1- ylmethyl)ethyl)octanamide) (2R,3R)-2,3-dihydroxybutanedioate; Octanamide, N-((1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1- pyrrolidinylmethyl)ethyl)-, (2R,3R)-2,3-dihydroxybutanedioate; N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide (2R,3R)-2,3-dihydroxybutanedioic acid. Grade: >98%. CAS No. 928659-70-5. Molecular formula: C50H78N4O14. Mole weight: 959.17. | |
| Elinafide | Elinafide, an isoquinoline derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed in anticancer studies. Synonyms: Elinafide; UNII-HL580335SI; Elinafide [INN]; 2-[2-[3-[2-(1,3-dioxobenzo[de]isoquinolin-2-yl)ethylamino]propylamino]ethyl]benzo[de]isoquinoline-1,3-dione; LU-79553. Grade: 98%. CAS No. 162706-37-8. Molecular formula: C31H28N4O4. Mole weight: 520.59. | |
| Elinogrel | Elinogrel is a P2Y12 antagonist displaying antiplatelet activity. Synonyms: 5-Chloro-N-[[[4-[6-Fluoro-1,4-dihydro-7-(methylamino)-2,4-dioxo-3(2H)-quinazolinyl]phenyl]amino]carbonyl]-2-thiophenesulfonamide. Grade: ≥98% by HPLC. CAS No. 936500-94-6. Molecular formula: C20H15ClFN5O5S2. Mole weight: 523.95. | |
| Elinzanetant | Elinzanetant is a neurokinin receptors antagonist that may help reduce the frequency and severity of hot flushes during menopause. Elinzanetant reduces Estradiol and Progesterone in Healthy Women. Synonyms: BAY 3427080; BAY-3427080; BAY3427080; NT 814; NT-814; NT814; GSK1144814A; GSK-1144814A; GSK 1144814A. Grade: 98%. CAS No. 929046-33-3. Molecular formula: C33H35F7N4O3. Mole weight: 668.66. | |
| Eliprodil | Eliprodil, a NR2B-NMDA receptor antagonist, was found to have neuroprotective activity in study of ischemia. Uses: Eliprodil is a nr2b-nmda receptor antagonist that was found to have neuroprotective activity in study of ischemia. Synonyms: -(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol, SL-82,0715; SL82,0715; SL 82,0715; SL-820715; SL820715; SL 820715; Eliprodil. Grade: 95%. CAS No. 119431-25-3. Molecular formula: C20H23ClFNO. Mole weight: 347.85. | |
| Elisartan | Elisartan, also known as HN-65021, is an orally active non-peptide prodrug of angiotensin II AT1 receptor antagonist HN-12206, and shows anti-hypertension activities. Uses: Angiotensin ii type 1 receptor blockers. Synonyms: 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-((ethoxycarbonyl)oxy)ethyl ester; HN 65021; HN-65021. CAS No. 149968-26-3. Molecular formula: C27H29ClN6O5. Mole weight: 553.01. | |
| Elisidepsin | Elisidepsin is a marine-derived, synthetic cyclic depsipeptide with potential antineoplastic activity. Elisidepsin is a derivative of a natural marine compound that belongs to a family of dehydro aminobutyric acid-containing peptides (kahalalides) isolated from the herbivorous marine mollusk Elysia rufescens. Although the primary mechanism of action has yet to be elucidated, this agent exhibits anti-proliferative activity in a wide variety of cancer cell types, including breast, colon, pancreas, lung, and prostate; it appears to induce oncolytic rather than apoptotic cell death. Synonyms: PM-02734; N-[(4S)-4-methylhexanoyl]-D-valyl-L-threonyl-L-valyl-D-valyl-D-prolyl-L-ornithyl-N-{(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-3,12-diisopropyl-19-methyl-2,5,8,11,14,17-hexaoxo-1-oxa-4,7,10,13,16-pentaazacyclononadecan-18-yl}-D-alloisoleucinamide. CAS No. 681272-30-0. Molecular formula: C75H124N14O16. Mole weight: 1477.90. | |
| Ellipticine hydrochloride | Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor. Ellipticine is a natural product isolated from the Australian evergreen tree of the Apocynaceae family. Synonyms: NSC 71795 hydrochloride; Ellipticine HCl; PZE. CAS No. 5081-48-1. Molecular formula: C17H15ClN2. Mole weight: 282.77. | |
| ELN318463 | ELN318463, a selective γ-secretase inhibitor of amyloid precursor protein (APP), has differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC50s of 12 and 656 nM for PS1 and PS2, respectively. It is 51-fold more selective for PS1. Synonyms: N-[(4-bromophenyl)methyl]-4-chloro-N-[(3R)-hexahydro-2-oxo-1H-azepin-3-yl]-Benzenesulfonamide; N-(4-Bromobenzyl)-4-chloro-N-[(3R)-2-oxo-3-azepanyl]benzenesulfonamide; Benzenesulfonamide, N-[(4-bromophenyl)methyl]-4-chloro-N-[(3R)-hexahydro-2-oxo-1H-azepin-3-yl]-. Grade: ≥98%. CAS No. 851600-86-7. Molecular formula: C19H20BrClN2O3S. Mole weight: 471.80. | |
| ELN318463 racemate | ELN318463 racemate is the racemate of ELN318463, which is a selective γ-secretase inhibitor of amyloid precursor protein (APP). Synonyms: Benzenesulfonamide, N-[(4-bromophenyl)methyl]-4-chloro-N-(hexahydro-2-oxo-1H-azepin-3-yl)-; N-(4-Bromobenzyl)-4-chloro-N-(2-oxo-3-azepanyl)benzenesulfonamide. Grade: ≥90%. CAS No. 851599-82-1. Molecular formula: C19H20BrClN2O3S. Mole weight: 471.80. | |
| ELN 441958 | ELN441958 is a novel, potent and selective bradykinin B1 receptor antagonist with Ki value of 0.26 nM. It competitively inhibited the binding of the agonist [3H]DAKD to the human B1 receptor in IMR-90 lung fibroblast cell membranes. It is highly selective for B1 over B2 receptors and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor. It also inhibited human μ-, δ-, κ- opioid receptors and muscarinic M1 receptor with Ki values of 0.13, 0.69, 1.5 and 0.37 μM, respectively. It exhibited good permeability and metabolic stability in vitro. It exhibited high oral bioavailability and moderate plasma half-lives in rats and rhesus monkeys. It does not inhibit the activation of the human bradykinin B2 receptor at concentrations up to 10 μM. It has a moderate clearance and volume of distribution in both species following i.v. administration, consistent with the high metabolic stability in rat, rhesus, and human microsomes. Uses: Eln441958 exhibited high oral bioavailability and moderate plasma half-lives. Synonyms: ELN441958; ELN 441958; ELN-441958; 7-Chloro-2-[3-[[9-(pyridin-4-yl)-3,9-diazaspiro[5.5]undecan-3-yl]carbonyl]phenyl]-2,3-dihydroisoindol-1-one. Grade: >98%. CAS No. 913064-47-8. Molecular formula: C29H29ClN4O2. Mole weight: 501.02. | |
| ELN 484228 | ELN 484228 is an α-Synuclein blocker with activity in cellular models of α-synuclein-mediated dysfunction such as Parkinson's Disease. Study showed that ELN484228 reduced synaptic levels of αSyn in neuronal cultures from both wild type rats and from transgenic mice overexpressing αSyn by not more than two-fold. Synonyms: ELN484228; ELN-484228; ELN 484228. N-(4-Fluorophenyl)benzenesulfonamide. Grade: 99%. CAS No. 312-63-0. Molecular formula: C12H10FNO2S. Mole weight: 251.28. | |
| ELND006 | ELND006 is one of the newest molecules to be reported on regarding the testing of the β-amyloid hypothesis. ELND006 is a novel oral γ-secretase inhibitor. At the 2010 Alzheimer's Association International Conference on Alzheimer's Disease in which ELND006 was reported to have an in vitro IC50 = 0.34 nM against APP and IC50 = 5.3 nM versus Notch signaling. Synonyms: ELND006; ELND-006; ELND 006. (4R)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline; UNII-7F5QGV49GL; ELND006; ELND-006; 959997-22-9; (R)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo(4,3-c)quinoline; (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline; 7F5QGV49GL; SCHEMBL486044; GTPL7337; CHEMBL2396778. CAS No. 1333990-84-3. Molecular formula: C20H14F5N3O2S. Mole weight: 455.07. | |
| ELND007 | ELND007 is a γ-secretase inhibitor. Synonyms: ELND007; ELND-007; ELND 007. (R)-4-cyclopropyl-8-fluoro-5-((6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline; ELND007; ELND-007; ELND 007. CAS No. 1444006-79-4. Molecular formula: C19H14F4N4O2S. Mole weight: 438.08. | |
| Elobixibat | Elobixibat is a potent and selective IBAT inhibitor under development for the treatment of chronic constipation and irritable bowel syndrome with constipation. Uses: Sodium-bile acid cotransporter-inhibitor. Synonyms: AZD-7806; AZD 7806; AZD7806; A 3309; A3309; A-3309; AJG-533; (2R)-N-[2-[[3,3-Dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl]oxy]acetyl]-2-phenylglycylglycine. Grade: ≥95%. CAS No. 439087-18-0. Molecular formula: C36H45N3O7S2. Mole weight: 695.89. | |
Our database is helping our users find suppliers everyday.
